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Abstract 
Background  The conventional cyclophosphamide-based treatment regimens for lupus 
nephritis (LN) are still not considered to be optimal treatments. The aim of this study was to 
evaluate the efficacy and safety of mizoribine, tacrolimus and corticosteroids combination 
therapy for LN.  
Methods  We retrospectively evaluated a combination treatment of mizoribine and 
tacrolimus with corticosteroids for the induction therapy of eight newly diagnosed systemic 
lupus erythematosus (SLE) patients with biopsy-proven LN.  
Results  All the patients were females, and their mean (SD) age was 48.5 (20) years. All 
eight patients (100%) had positive anti-double-stranded DNA antibody titers, and four 
(50.0%) were nephrotic. The mean (SD) serum creatinine and daily proteinuria levels were 
0.72 (0.4) mg/dL (range, 0.33–1.55 mg/dL) and 4.56 (2.8) g (range, 0.77–8.2 g), respectively. 
By month 2, significant improvements in the anti-double-strand DNA antibody titers, levels 
of proteinuria, serum albumin, and C3, and SLE disease activity index score were observed. 
By month 6, seven patients (87.5%) were in complete remission with normalized levels of 
both proteinuria and serum creatinine. 
Conclusions  This pilot study suggests that mizoribine and tacrolimus treatment with 
corticosteroids is well-tolerated and may prove to be an optimal alternative 
remission-inducing regimen for LN.  
 
Keywords Induction therapy, Lupus nephritis, Mizoribine, Multitarget therapy, Systemic 
lupus erythematosus, Tacrolimus 
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Introduction 
Systemic lupus erythematosus (SLE) is a potentially fatal autoimmune disease that 
involves multiple vital organs. SLE is associated with diverse clinical features that range 
from rash and arthritis to cytopenia, serositis, nephritis, seizures and psychosis. Lupus 
nephritis (LN) is a major manifestation of SLE and has the worst prognosis [1–5]. Since an 
early response to immunosuppressive therapy is predictive of a good long-term renal outcome 
[5–7], regimens that induce rapid remission are needed. 
The combination of corticosteroids and cyclophosphamide pulse therapy has been the 
standard therapy for diffuse proliferative LN. However, a significant number of LN patients 
(17–57%) fail to achieve complete or partial remission despite receiving the standard therapy 
[8–13]. Only a small percentage of patients (8.1–8.6%) treated with mycophenolate mofetil 
(CellCept, MMF) or intravenous cyclophosphamide achieved complete remission, strictly 
defined as return to normal serum creatinine, urine protein ≤ 0.5 g/d, and inactive urinary 
sediment, in a large multinational study [14]. Indeed, the standard therapy for SLE has its 
limitations because of the heterogeneous disease mechanisms that underlie SLE. Furthermore, 
in comparison with patients who receive corticosteroids alone, patients receiving 
cyclophosphamide-based treatment regimens show higher long-term renal survival rates, but 
not higher overall survival rates [11]. The use of cyclophosphamide-based treatment 
regimens is limited by the potentially severe and toxic adverse effects, which include bone 
marrow suppression, hemorrhagic cystitis, opportunistic infections, malignant diseases, and 
premature gonadal failure [8, 15]. Since conventional treatments for LN have not provided 
satisfactory clinical outcomes, alternative treatments are required. 
Mizoribine (Bredinin, MZB) is a purine synthesis inhibitor with similar activity to MMF, 
and has been used in Japan for patients undergoing renal transplantation and in patients with 
rheumatoid arthritis, LN and nephrotic syndrome [16–22]. Mizoribine oral pulse therapy has 
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been reported to be of benefit in patients with LN disease flare-up. Furthermore, mizoribine 
appears to be safer than cyclophosphamide and other immunosuppressive agents.  
Tacrolimus (Prograf, FK506) is a T-cell-specific calcineurin inhibitor, and has been 
increasingly used in not only transplant medicine but also autoimmune diseases such as SLE 
[23–31], rheumatoid arthritis [32], inflammatory bowel disease, and myasthenia gravis. 
MMF is a selective inhibitor of B-cell and T-cell proliferation, and a combined therapy 
comprising administration of steroids, MMF, and tacrolimus, which had been applied for 
patients undergoing organ transplantation, was successfully used for patients with severe LN 
[33].  
Since clinical use of MMF and cyclophosphamide for LN has not yet been approved as a 
health insurance treatment in Japan, we used a combination regimen of mizoribine and 
tacrolimus with corticosteroids for induction treatment of LN. In the present study, we 
retrospectively evaluated a combination regimen of mizoribine and tacrolimus with 
corticosteroids for the induction therapy of newly diagnosed SLE patients with biopsy-proven 
LN. 
 
Methods 
We retrospectively studied eight consecutive patients with newly diagnosed SLE and LN 
who provided oral informed consent. The patients were treated at the Department of Internal 
Medicine, Himeji Red Cross Hospital (Himeji, Japan). All the patients fulfilled the revised 
ACR criteria for SLE and had biopsy-proven LN.  
All patients received intravenous methylprednisolone pulse therapy (0.5 g/d for 3 d) at the 
beginning, followed by oral prednisolone. The daily dosage of prednisolone was started at 60 
mg/d (80 mg/d for patients weighing above 60 kg) and then reduced by 10 mg/d every week 
to reach 30 mg/d, which was followed by further tapering by 5 mg/d at 2-week intervals until 
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20 mg/d was reached. Further tapering to 5 mg/d was allowed if the patient’s condition was 
stable. The initial tacrolimus dose was 3 mg/d once daily. Blood trough concentrations were 
measured at weeks 1, 2, 3 and 4 and months 2, 4, 5 and 6, and the dosage was titrated to 
maintain a blood concentration below 10 ng/mL. Administration of mizoribine was initiated 
at a dose of 300 mg/d once daily for 3 d per week. Blood peak concentrations were measured 
if necessary, and the dosage (maximum, 300 mg/d) was titrated to maintain an upper blood 
concentration of 1.0 μg/mL [20, 34]. When the patients showed complete remission of SLE, 
either mizoribine or tacrolimus was stopped and another immunosuppressive agent was 
continued for the maintenance therapy. 
The primary efficacy parameter was complete remission at 6 months, which was defined 
as proteinuria level < 0.2 g/d and normal level of serum creatinine or no more than 15% 
above the baseline value. A secondary efficacy parameter was SLEDAI [35] remission at 6 
mo, which was defined as an SLE disease activity index (SLEDAI) score of 0. Additional 
secondary efficacy parameters examined included proteinuria level, serum creatinine level, 
estimated glomerular filtration rate (eGFR), serum C3 level, anti-double-stranded DNA 
antibody titer, serum albumin level, hemoglobin level, and SLEDAI score. Therapeutic 
responses were determined at 2, 4, and 6 mo. This study was approved by the ethical 
committee of our hospital. 
 
Results 
All the patients were females, and their mean (SD) age was 48.5 (20.3) years. At the start 
of the treatment, all eight (100%) patients had positive anti-double-stranded DNA antibody 
titers, a mean (SD) serum creatinine level of 0.72 (0.4) mg/dL (range, 0.33–1.55 mg/dL), and 
a mean (SD) daily proteinuria level of 4.56 (2.8) g (range, 0.77–8.2 g). In addition, four 
(50.0%) patients were nephrotic, four (50.0%) were hypertensive, and one (12.5%) had an 
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elevated serum creatinine level at start of the treatment (Table 1). The numbers of cases in the 
categories of the International Society of Nephrology (ISN)/Renal Pathology Society (RPS) 
2003 criteria for the classification of LN were as follows: class II, one (12.5%); class III, 
three (37.5%); class IV-S, 0 (0%); class IV-G, one (12.5%); and class V: three (37.5%). After 
6 mo of therapy, complete remission and SLEDAI remission were achieved in seven (87.5%) 
and three (37.5%) patients, respectively (Figure 1). Significant improvements in the urine 
protein levels, C3 levels and SLEDAI scores were observed in comparison with the baseline 
values, starting at month 2 (Table 2, Figure 2). The anti-double-stranded DNA antibody titers 
at 6 mo were normalized in seven (87.5%) patients. Mizoribine and tacrolimus were 
generally well-tolerated in most cases, except three patients whose serum creatinine levels 
increased (Table 3). However, all cases showed improvement with reduced doses of 
tacrolimus. 
 
Discussion 
Renal involvement occurs in approximately 50% of patients with SLE, and LN remains a 
predominant cause of morbidity and mortality. Therapeutic management of SLE is based on 
the type and severity of organ involvement. The ideal therapy for LN should induce an early 
response and remission, prevent flare-ups, have minimal adverse effects, and result in 
reductions in mortality and end-stage renal disease [36].  
In the present study, we found that a 6-m course of a combination therapy of mizoribine 
and tacrolimus with corticosteroids is a safe and effective treatment for patients with LN. The 
suitability of cyclophosphamide-based treatment regimens, which are the standard therapy for 
LN, remains a matter of debate, and alternative treatments are therefore required. In 2008, 
Bao et al. [33] reported the benefits of multitarget therapy (MMF and tacrolimus with 
corticosteroids) in cases of severe LN (class V + IV). Multitarget therapy is possibly more 
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effective for LN because SLE is an extremely heterogeneous disorder. The clinical use of 
MMF has not yet been approved, except for conditioning therapy before transplantation, by 
the Ministry of Health and Welfare in Japan. Mizoribine is a purine synthesis inhibitor with 
similar activity to MMF, and we therefore used mizoribine instead of MMF for the treatment 
of LN. A correlation between the peak mizoribine blood concentration and the clinical 
response to the therapy has been observed in patients with LN [20], and to ensure the peak 
concentration in our patients, we administered mizoribine 300 mg/d once daily for 3 d per 
week. The mizoribine blood concentrations in the patients administered using this treatment 
protocol were above the target levels. 
By month 12, complete remission and SLEDAI remission were achieved in eight (100%) 
and five (62.5%) patients, respectively. Even more surprisingly, microalbuminuria was 
normalized in five (62.5%) patients (data not shown). With respect to the ultimate outcome of 
LN, the patient survival rates at 10 years were reported to be 95% for patients in complete 
remission, 76% for patients in partial remission, and 41% for patients with no remission [5]. 
Although complete remission in that study was defined as proteinuria level <0.33 g/d and 
serum creatinine level ≤1.4 mg/dL, we defined complete remission more strictly as 
normalization of proteinuria level (< 0.2 g/d) and serum creatinine level in the present study. 
Considering patients directed to a treatment target, the remission in both renal and serological 
parameters observed in our study will definitely lead to better outcomes. 
Owing to the long-term benefits, risks, and overall costs of the combination therapy, 
patients who showed SLEDAI remission after this combination therapy received maintenance 
therapy with one immunosuppressive agent. In a previous study, the occurrence of renal 
flare-ups was the strongest predictor of end-stage renal disease for patients who had once 
been in remission, and independent predictors of renal flare-ups were persistently low C3 
levels despite the induction therapy and an absence of azathioprine maintenance therapy [12]. 
8 
 
Tacrolimus treatment may be related to a lower risk of lupus flare-up [25], while beneficial 
effects of long-term treatment with mizoribine were also reported [19]. Therefore, both 
mizoribine and tacrolimus may be suitable as optional agents for the maintenance treatment 
for LN after this combination induction therapy. Furthermore, in comparison with the 
conventional treatments performed at our hospital, combination therapy may contribute to a 
lower cumulative prednisolone dosage and a shorter duration of hospital stay (data not 
shown).  
There are several limitations of this study. First, the sample size was small and the data 
were confined to 6 m. Further randomized controlled trials are needed to compare our 
multitarget regimen with standard regimens for LN. Second, although we recruited 
consecutive patients with a mean daily proteinuria level of 4.56 g, only four (50%) patients 
had active proliferative LN. The sample size was too small to evaluate the therapeutic 
response in each type of biopsy-proven group. Third, urinary sediments were not included as 
a definition of the treatment response in this study because we considered that normalization 
of proteinuria takes longer than that of urinary sediments. Fourth, it remains unclear which 
immunosuppressive agents should be chosen as the maintenance therapy for different types of 
LN. Finally, although the dosages of mizoribine and tacrolimus administered to our patients 
appeared to be well-tolerated, the optimal dosage regimens of mizoribine and tacrolimus 
remain unclear.  
In summary, our findings suggest that the combined use of two well-tolerated 
immunosuppressive agents with different activities for induction therapy of LN appears to be 
highly efficacious. Renal remission was induced by 6 m for almost all patients, who required 
a lower cumulative prednisolone dosage. This pilot induction regimen may be applied to 
various types of LN. Further studies are required for assessment of these expensive 
immunosuppressive agents in the treatment of LN. Physicians should thoroughly consider all 
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possible benefits, theoretical risks, and overall costs of each treatment regimen in each 
individual to provide the best care for their patients. 
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Figure legends 
Fig. 1. Remission rates with the combination therapy. Complete remission was defined as 
proteinuria level < 0.2 g/d and normal serum creatinine level or no more than 15% above the 
baseline value. SLEDAI remission was defined as a SLEDAI score of 0. The therapeutic 
responses were determined at 2, 4, and 6 mo. 
 
Fig. 2. Changes in biochemical parameters after treatment. Additional secondary efficacy 
parameters examined included proteinuria level (a), serum creatinine level (b), serum C3 level 
(c), anti-double-stranded DNA antibody titer (d), and SLEDAI score (e). The therapeutic 
responses were determined at 2, 4, and 6 m. Each line represents an individual patient. 
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Tables 
Table 1. Baseline characteristics of the patients treated with a combination of mizoribine and tacrolimus 
 
Age at lupus nephritis, years 48.5 (20.3); range, 22–70 
Females, number (%) 8 (100) 
Systemic lupus erythematosus duration, months 1.1 (2.1); range, 0–5 
First-time nephritis, number (%) 8 (100) 
Extrarenal features, number (%)  
   Musculoskeletal 4 (50) 
   Mucocutaneous 4 (50) 
   Neuropsychiatric 0 (0) 
   Hematologic 8 (100) 
ISN/RPS classification Class II: 1, class III: 3, class IV-G: 1, class V: 3  
Anti-double-strand DNA, number (%) 8 (100) 
Anti-double-strand DNA, IU/L 186 (129); range, 48–400  
Hemoglobin, g/dL  11.1 (1.5); range, 9.4–13.7  
Serum creatinine, mg/dL 0.72 (0.4); range, 0.33–1.55 
eGFR, ml/min per 1.73m2 89.5 (50.8); range, 27.2–178  
Serum albumin, g/dL  2.69 (0.7); range, 1.6–3.8  
Serum C3 level, mg/dL  41.3 (16.4); range, 23–68 
Proteinuria, g/day 4.56 (2.8); range, 0.77–8.2 
Nephrotic syndrome, number (%) 4 (50) 
Active urinary casts, number (%) 7 (88) 
Hypertension, number (%) 4 (50) 
SLEDAI scores 22.0 (2.1); range, 20–26 
 
ISN/RPS classification, International Society of Nephrology/Renal Pathology Society 2003 criteria for the 
classification of lupus nephritis; SLEDAI, systemic lupus erythematosus disease activity index. 
Data are shown as mean (SD). 
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Table 2. Changes in the biochemical parameters after treatment 
 
 Baseline Month 2 Month 4 Month 6 
Proteinuria, g/day 4.56 (2.8) 0.09 (0.1)** 0.34 (0.7)** 0.20 (0.3)** 
Nephrotic syndrome, number 
(%) 
4 (50) 0 (0) 0 (0) 0 (0) 
Serum albumin, g/dL 2.69 (0.7) 3.89 (0.3)** 3.94 (0.5)** 4.13 (0.4)** 
Serum C3 level, mg/dL 41.3 (16.4) 68.8 (22.1)** 83.6 (22.8)** 85.4 (22.5)** 
Anti-double-strand DNA, IU/L 186 (129) 16.7 (16.9)** 11.6 (9.6)** 9.3 (7.4)** 
Serum creatinine, mg/dL 0.72 (0.4) 0.84 (0.4) 0.72 (0.2) 0.70 (0.2) 
eGFR, ml/min per 1.73m2 89.6 (50.8) 68.7 (32.1) 76.0 (31.9) 77.5 (31.8) 
Hemoglobin, g/dL 11.1 (1.5) 12.0 (2.1) 12.4 (1.5) * 12.6 (1.5)** 
SLEDAI scores 22.0 (2.1) 3.3 (2.8)** 2.8 (4.3)** 2.0 (1.9)** 
 
Data are shown as means (SD). *P<0.05, **P<0.01 
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Table 3. Dosages, blood concentrations and adverse effects 
 Age/sex 
(years) 
ISN/RPS 
classification 
Mizoribine 
dosage at 6 
months 
(mg/d) 
Peak 
mizoribine 
concentration 
(μg/mL) 
Tacrolimus dosage 
at 6 months 
(mg/d) 
Trough Tacrolimus 
concentration 
(ng/mL) 
PSL dosage at 
6 months 
(mg/d) 
Clinical response 
at 6 months 
Adverse effects 
Patient 1 32/F class V 300 1.81 3 3.77 15 CR  Dyslipidemia 
Patient 2 40/F class V 300 1.16 3 5.86 15 CR Dyslipidemia 
Patient 3 27/F class IV-G (A) 300 ND 3 → 2 7.07 → 3.95 10 None Increase in serum 
creatinine 
Hypertension 
Diabetes mellitus 
Patient 4 66/F class II 300 ND 3 8.22 13 CR None 
Patient 5 22/F class V 300 ND 3 9.03 10 CR + SLEDAI-R Dyslipidemia 
Patient 6 62/F class V + III 
(A/C) 
300 1.96 3 → 2 7.70 → 3.43 10 CR Increase in serum 
creatinine 
Diabetes mellitus 
Dyslipidemia 
Patient 7 69/F class III (A/C) 300 1.96 3 → 2 → stopped 3.80 → 2.69 10 CR + SLEDAI-R Increase in serum 
creatinine 
Diabetes mellitus 
Dyslipidemia 
Patient 8 70/F class III (A/C) 300 ND 3 → 2 6.33 → 2.90 11 CR + SLEDAI-R Diabetes mellitus 
HZV 
CR, complete remission; SLEDAI-R, SLEDAI remission; HZV, herpes zoster virus
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Fig 2. Changes in biochemical parameters after treatment 
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